Physician profile
Douglas U Blank
NPI 1871598631
$11,379.59
in general payments reported to CMS, 2019-2025
34 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $589 · 2021: $1,170 · 2022: $1,954 · 2023: $2,505 · 2024: $2,570 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,700 · Travel and Lodging: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,700.38 |
| Travel and Lodging | $1,118.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,219.07 | 2019-2025 | Triclip, Mitraclip, Jot Dx |
| Boston Scientific Corporation | $2,686.36 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $1,036.58 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $530.25 | 2021-2025 | Micra, Resolute Onyx, Cobalt Dr Mri Surescan |
| Actelion Pharmaceuticals US, INC. | $516.92 | 2019-2025 | Uptravi, Opsumit |
| Abiomed | $397.05 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $320.38 | 2019-2025 | |
| Pfizer INC. | $318.89 | 2019-2025 | |
| United Therapeutics Corporation | $317.74 | 2019-2024 | Orenitram |
| Lantheus Medical Imaging, INC. | $290.72 | 2019-2024 | |
| Cvrx, INC. | $261.77 | 2021-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $249.62 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $229.67 | 2019-2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $196.97 | 2024 | Inpefa |
| Inspire Medical Systems, INC. | $111.62 | 2024 | Inspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $105.04 | 2022-2025 | Amvuttra |
| Edwards Lifesciences Corporation | $74.99 | 2020-2021 | |
| Livanova USA, INC. | $60.45 | 2023 | Lifesparc |
| Bayer Healthcare Pharmaceuticals INC. | $55.21 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.76 | 2024-2025 | Lifevest |
| Amgen INC. | $48.61 | 2019-2021 | |
| Baxter Healthcare | $43.68 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $36.11 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $35.26 | 2024-2025 | Injectafer |
| Ge Healthcare | $29.73 | 2023 | |
| Esperion Therapeutics, INC. | $25.74 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $21.92 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $20.96 | 2025 | |
| Genzyme Corporation | $17.80 | 2024 | |
| Philips North America LLC | $16.55 | 2025 | Mcot |
| Arbor Pharmaceuticals, INC. | $16.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2023 | Farxiga |
| Lilly USA, LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.